We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+23.52%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$625M
AUM Growth
+$113M
Cap. Flow
+$47.8M
Cap. Flow %
7.65%
Top 10 Hldgs %
69.45%
Holding
35
New
10
Increased
5
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
FDMT icon
4D Molecular Therapeutics
FDMT
+$55.2M
2
DYN icon
Dyne Therapeutics
DYN
+$25.6M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$19.7M
4
PHVS icon
Pharvaris
PHVS
+$12.8M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.2M

Top Sells

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$27M
2
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$23.5M
3
JBIO
Jade Biosciences
JBIO
+$16.8M
4
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$15.9M
5
ANNX icon
Annexon
ANNX
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
26
Spyre Therapeutics
SYRE
$8.54B
$2.86M 0.46%
+253,729
New +$1.2M
BDTX icon
27
Black Diamond Therapeutics
BDTX
$96.8M
$1.79M 0.29%
+353,629
New +$722K
RLYB icon
28
Rallybio
RLYB
$84.5M
$1.52M 0.24%
33,567
– –
AFMD
29
DELISTED
Affimed
AFMD
$855K 0.14%
142,857
– –
AVTX icon
30
Avalo Therapeutics
AVTX
$965M
$444K 0.07%
5,208
+1,041
+25% +$701K
ANNX icon
31
Annexon
ANNX
$834M
– –
-3,220,050
Closed -$12.4M
JBIO
32
Jade Biosciences
JBIO
$1.2B
– –
-23,826
Closed -$16.8M
FULC icon
33
Fulcrum Therapeutics
FULC
$273M
– –
-1,307,094
Closed -$3.73M
DICE
34
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-819,000
Closed -$23.5M
VECT
35
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
– –
-1,866,000
Closed -$15.9M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q2 2023 Portfolio in Review

As of Q2 2023, VR Adviser held 35 positions worth $625M, up 22% from $512M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

VR Adviser deployed $47.8M of net new capital in Q2 2023, opening 10 new positions and adding to 5 existing holdings. Its largest new stake was 4D Molecular Therapeutics: 3,000,000 shares worth $54.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Pliant Therapeutics, an estimated $27M trimmed.

  • VR Adviser's largest Q2 2023 buy was 4D Molecular Therapeutics: 3,000,000 shares worth $54.2M.
  • VR Adviser added most to Merus in Q2 2023, an estimated $10.9M increase.
  • VR Adviser's biggest Q2 2023 reduction was Pliant Therapeutics, cutting an estimated $27M.
  • VR Adviser fully exited DICE Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $23.5M.
  • VR Adviser's ten largest holdings make up 69% of its $625M portfolio in Q2 2023.
  • VR Adviser opened 10 new positions and closed 5 in Q2 2023.
  • VR Adviser's portfolio value rose 22% quarter-over-quarter to $625M.

Based on VR Adviser's 13F filing for Q2 2023, filed 11 Aug 2023.